Intimation of Acquisition under Regulation 30 of SEBI (LODR) Reg. 2015
Awaiting price reaction for this filing.
Authum Investment & Infrastructure Ltd (NSE: AIIL | BSE: 539177) is acquiring 39,27,000 equity shares of OneSource Specialty Pharma Limited (NSE: ONESOURCE | BSE: 544292) from Devicam Capital LLP and Pronomz Ventures LLP. The stake represents 3.43% of voting rights in OneSource on a fully diluted basis, with an aggregate fair market value of about INR 2,028 (crores) based on NSE prices as on June 13, 2025. OneSource, formerly known as Stelis Biopharma, is India's first specialty pharma CDMO with a net worth of Rs 5,880 crores and FY25 turnover of Rs 1,444.8 crores, showing sharp revenue growth from Rs 171.9 cr in FY24 and Rs 41 cr in FY23. The deal is a commercial transaction, is not a related party deal, requires no regulatory approvals, and is slated to complete on June 13, 2025.
Authum is deploying significant capital into a high-growth listed pharma CDMO, which diversifies its portfolio and provides exposure to the booming contract manufacturing space. At only 3.43%, this is a minority financial stake and is unlikely to trigger an open offer, but it signals Authum's confidence in OneSource's growth trajectory.